تصفح College of Medicine حسب الموضوع "immune checkpoint inhibitors"
السجلات المعروضة 1 -- 6 من 6
-
Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer.
( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2023 , Article Review)Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian ... -
Molecular profiling of the metaplastic spindle cell carcinoma of the breast reveals potentially targetable biomarkers
( Elsevier , 2020 , Article)IntroductionSpindle cell carcinoma is a rare subtype of metaplastic breast cancer (MBC), with triple-negative (TNBC: ER-/PR-/Her2-) phenotype. It is associated with a marked resistance to conventional chemotherapy and has ... -
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
( AME Publishing Company , 2017 , Article)CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors -
PD-L1 status in breast cancer: Current view and perspectives.
( Elsevier , 2019 , Article)Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ... -
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2019 , Article Review)The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously ... -
An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
( Multidisciplinary Digital Publishing Institute (MDPI) , 2023 , Article)Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50. Immune checkpoint inhibitors (ICI) treatment has shown promising results in MCC patients. ...